💰钛媒体•較早收集於 61m
Isomorphic Labs 獲得 AI 製藥領域創紀錄融資
💡一項證明 AI 驅動藥物發現商業可行性的重大融資里程碑。
⚡ 30-Second TL;DR
有什麼變化
AI 製藥領域創紀錄的 143 億人民幣融資
為什麼重要
標誌著資本正大規模轉向 AI 原生製藥公司，有望加速藥物研發進程。
下一步行動
追蹤 Isomorphic Labs 發表的論文，了解其在蛋白質折疊與藥物設計方面的研究方法。
誰應關注：Researchers & Academics
關鍵要點
- •AI 製藥領域創紀錄的 143 億人民幣融資
- •專注於藥物研發的範式革命
- •利用 AI 進行複雜生物數據分析
🧠 深度解析
Web-grounded analysis with 19 cited sources.
🔑 增強重點摘要
- •The record funding is a $2.1 billion Series B round, announced on May 12, 2026, led by Thrive Capital with participation from existing backers Alphabet and GV, and new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
- •Isomorphic Labs' proprietary AI drug design engine, IsoDDE, extends beyond protein structure prediction to actively generate novel molecules from scratch and predict binding affinities with superior accuracy and speed compared to traditional methods.
- •A significant milestone was achieved in January 2026 with the FDA clearance of ISM8969, one of Isomorphic Labs' AI-designed drugs, for human clinical trials.
- •The company utilizes Google Cloud's AI Hypercomputer, including TPUs and GPUs orchestrated by Google Kubernetes Engine, to provide scalable infrastructure that accelerates inference workloads by up to 50%.
- •Isomorphic Labs has established strategic collaborations with major pharmaceutical companies such as Novartis, Eli Lilly, and Johnson & Johnson, alongside developing an internal drug candidate pipeline focused on oncology and immunology.
🛠️ 技術深入
- Isomorphic Labs' core technology is its unified AI drug design engine, IsoDDE, which builds upon and extends the capabilities of AlphaFold technology.
- AlphaFold 3, released in May 2024 in collaboration with Google DeepMind, can predict the structures and interactions of all of life's molecules, including proteins, DNA, RNA, ligands, and antibodies, with high accuracy.
- IsoDDE goes beyond structure prediction, focusing on designing new molecules from first principles and targeting disease mechanisms that have been challenging for traditional medicinal chemistry.
- The engine demonstrates predictive accuracy for small molecule binding-affinities, outperforming physics-based methods in speed and cost efficiency, and can identify new binding pockets on target proteins using only amino acid sequences.
- Isomorphic Labs' infrastructure leverages Google Cloud's AI Hypercomputer, managing fleets of TPUs and GPUs orchestrated by Google Kubernetes Engine to achieve rapid scalability and accelerate inference workflows by up to 50%.
- The AI models are designed to be generalizable, working across multiple therapeutic areas and drug modalities (e.g., small molecules, biologics) in an end-to-end, target and disease-agnostic manner.
- The company maintains a unique, curated collection of life science data, referred to as a 'dataverse,' which powers its research environment and supports massive volumes of in-silico experiments.
🔮 前景展望AI analysis grounded in cited sources
AI-designed drugs will reach clinical success faster and at a lower cost, disrupting traditional pharmaceutical R&D timelines.
Isomorphic Labs' AI-first approach, exemplified by its IsoDDE engine and the rapid progression of an AI-designed drug (ISM8969) to human clinical trials, aims to significantly compress the traditional drug discovery timeline and reduce associated costs, setting a new industry benchmark.
The pharmaceutical industry will see a broader shift towards AI-first drug discovery platforms, increasing competition and innovation.
The substantial investment in Isomorphic Labs and its early clinical validation will pressure traditional pharmaceutical companies to further integrate AI, potentially making AI a 'first pass' for drug discovery with lab work serving as confirmation, thereby accelerating industry-wide innovation.
⏳ 時間線
2021-02
Isomorphic Labs incorporated.
2021-11
Isomorphic Labs officially announced by Alphabet as a DeepMind spin-off, with Demis Hassabis as CEO.
2024-01
Strategic research collaborations announced with Novartis and Eli Lilly.
2024-05
Google DeepMind and Isomorphic Labs release AlphaFold 3.
2025-03
Raised $600 million in its first external funding round (Series A) led by Thrive Capital.
2026-01
AI-designed drug, ISM8969, receives FDA clearance for human clinical trials.
2026-02
Announced its Drug Design Engine (IsoDDE), an evolution beyond AlphaFold 3.
2026-05
Secured $2.1 billion in Series B funding.
📎 來源 (19)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
- Google Search Source
📰
AI 週報
閱讀本週精選 AI 大事摘要 →
👉相關動態
AI 策展新聞聚合。所有內容版權歸原始發布者所有。
原始來源： 钛媒体 ↗